Raleigh-based pharmaceutical company BioDelivery Sciences International (Nasdaq: BDSI) has scored a new managed care contract with Texas Medicaid for its opioid dependence drug Bunavail.
The latest contract marks the sixth for BDSI since July, according to the company, which has previously said it expects Bunavail to achieve profitability by the end of 2017.
Just last month, BDSI announced three new managed care contracts for Bunavail, which President and CEO Mark Sirgo said at the time were “primarily…
Raleigh-based pharmaceutical company BioDelivery Sciences International (Nasdaq: BDSI) has scored a new managed care contract with Texas Medicaid for its opioid dependence drug Bunavail.
The latest contract marks the sixth for BDSI since July, according to the company, which has previously said it expects Bunavail to achieve profitability by the end of 2017.
Just last month, BDSI announced three new managed care contracts for Bunavail, which President and CEO Mark Sirgo said at the time were “primarily…